As of Thursday close, Nektar Therapeutics’s (NASDAQ:NKTR) stock was up $0.14, moving up 3.90 percent to $3.73. The average number of shares traded per day over the past five days has been 3,746,020 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.71 fall in that time frame. In the last twenty days, the average volume was 5,040,400, while in the previous 50 days, it was 4,653,178.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
Since last month, NKTR stock retreated -34.68%. Shares of the company fell to $3.52 on 05/12/22, the lowest level in the past month. A 52-week high of $19.56 was reached on 01/03/22 after having rallying from a 52-week low of $3.53. Since the beginning of this year, NKTR’s stock price has dropped by -72.39% or -$9.78, and marked a new high 1 time. However, the stock has declined by -80.93% since its 52-week high.
Nektar Therapeutics (NKTR) last reported insider trading activity 86 days ago on Feb 16. Zalevsky Jonathan, the Chief R&D Officer of the company, disposed of 10,912 shares for $10.95 on Feb 16. It resulted in a $119,486 divestment by the insider. Wilson Mark Andrew sold 3,661 shares at an average price of $10.95 on Feb 16. The insider now owns 121,075 shares following the transaction. On Feb 16, SVP & Chief Accounting Officer Thomsen Jillian B. sold 2,363 shares at $10.95 apiece. The transaction was valued at $25,875.
The stock’s beta is 1.34. Besides these, the trailing price-to-sales (P/S) ratio of 6.96, the price-to-book (PB) ratio of 0.86.
In the three months ended September 29, Nektar Therapeutics’s quick ratio stood at 6.80, while its current ratio was 7.00, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 75.60% percent. Based on annual data, NKTR earned $77.01 million in gross profit and brought in $101.91 million in revenue.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. NKTR’s revenue rose 4.71% to $25.01 million during the quarter, while net income inched up to $24.82 million. While analysts expected Nektar Therapeutics to report -$0.8 quarterly earnings, the actual figure was -$0.7 per share, beating the consensus estimate by 12.50%. During the quarter, the company generated -$111.55 million in EBITDA. The liabilities of Nektar Therapeutics were 416.23 million at the end of its most recent quarter ended September 29, and its total debt was $146.46 million. The value of shareholders’ equity is $186.27 million.
This quick technical analysis looks at Nektar Therapeutics’s (NKTR) price momentum. With a historical volatility rate of 110.93%, the RSI 9-day stood at 32.73% on 12 May.
With respect to its five-day moving average, the current Nektar Therapeutics price is down by -15.99% percent or -$0.71. At present, NKTR shares trade -39.55% below its 20-day simple moving average and -72.71% percent below its 100-day simple moving average. However, the stock is currently trading approximately -65.30% below its SMA50 and -77.05% below its SMA200.
Stochastic coefficient K was 14.00% and Stochastic coefficient D was 15.59%, while ATR was 0.41. Given the Stochastic reading of 16.80% for the 14-day period, the RSI (14) reading has been calculated as 33.11%. As of today, the MACD Oscillator reading stands at -0.42, while the 14-day reading stands at -0.49.